NCT06321211Completed
Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD
Development of a Novel Asian Mediterranean Diet and Its Acceptability in Non- Alcoholic Fatty Liver Disease (NAFLD)- a Pre-intervention Study
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
The goal of this pre-intervention study is test the acceptability of Asian version of the Mediterranean diet to NAFLD patients. The main question\[s\] it aims to answer are: 1. Whether Asian version of the Mediterranean diet that retains the nutritional composition and can be developed by mapping the components of the Mediterranean diet and finding substitute ingredients commonly eaten in Southeast Asia. 2. Whether the 4-week menu cycle of newly developed novel Asian Mediterranean diet is acceptable among Singaporean local population. Participants will participate in taste test sessions to find out if the Asian Mediterranean diet meals are acceptable to people with NAFLD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 30 (actual)
- First submitted
- 29 Feb 2024
- Start date
- 15 Apr 2024
- Primary completion date
- 16 Oct 2024
- Lead sponsor
- Singapore Institute of Technology
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06321211
What you commit to
- Study type: Observational
- Participants enrolled: 30
- From 15 Apr 2024 to the primary completion date, 16 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Secondary causes of NAFLD (e.g. medication-induced)
- Current use of weight loss medications
Other illness
- Other liver diseases (viral hepatitis, auto-immune or cholestatic liver disease, Wilson's disease, hemochromatosis, alpha-1 anti-trypsin deficiency)
- Renal failure
- Food allergy/intolerances/restrictions
Lab values
- Unstable diabetes (HbA1c \>8.5%)
Other
- Unstable body weight (variation \>5% within the preceding 3 months)
- Inability to provide informed consent
- Pregnancy and lactation
- Problems with tasting and smelling
Who the study is looking for
- Diagnosis of NAFLD, as determined clinically by imaging evidence of hepatic steatosis on ultrasound/CT/MRI
Age in the registry: 21 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Singapore Institute of Technology Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.